Onco Therapies, a wholly owned subsidiary of pharma company Strides Arcolab, has received two US FDA (Food and Drug Administration) approvals for ‘Fluorouracil Injection USP’.

Fluorouracil is part of the oncology portfolio licensed to Pfizer for the US market and expected to be launched shortly, a press statement said.

Fluorouracil is a chemotherapy drug which interferes with cells making DNA and RNA, and stops the growth of cancer cells. It is used to treat several types of cancer including colon, rectum, and head and neck cancers.

According to the statement, Fluorouracil is among the products in the drug shortage list of USFDA. According to IMS data, the US market for generic Fluorouracil is approximately $14 million.